Alarcón-Segovia D, Ruiz-Argüelles G J, Garcés-Eisele J, Ruiz-Argüelles A
Instituto nacional de la Nutrición Salvador Zubirán, México, DF, México.
J Rheumatol. 1996 Dec;23(12):2162-5.
The mechanism of thrombophilia in patients with antiphospholipid antibodies (aPL) is not clearly understood. A number of contributing factors have been described, but more than one may be operative. It was recently found that aPL may cause the acquired activated protein C resistance phenotype, whereas in familial thrombophilia, activated protein C resistance frequently results from a point mutation in the factor V gene (replacing arginine 506 with a glutamine) that leads into the (R-506-Q), the so-called Leiden mutation, that produces a mutated factor V, resistant to the catalytic action of activated protein C, otherwise normal in its procoagulant properties. We describe one patient heterozygous for the activated protein C resistance genotype with a familial form of primary antiphospholipid syndrome, who had a nephew who died with this disease. In individuals who are heterozygous for the factor V Leiden mutation, the presence of aPL may cause further activated protein C resistance, resulting in increased thrombophilia.
抗磷脂抗体(aPL)患者血栓形成倾向的机制尚不清楚。已经描述了许多促成因素,但可能不止一个起作用。最近发现,aPL可能导致获得性活化蛋白C抵抗表型,而在家族性血栓形成倾向中,活化蛋白C抵抗通常是由因子V基因中的一个点突变(精氨酸506被谷氨酰胺取代)导致的,即(R-506-Q),所谓的莱顿突变,它产生一种突变的因子V,对活化蛋白C的催化作用具有抗性,但其促凝特性正常。我们描述了一名患有家族性原发性抗磷脂综合征且活化蛋白C抵抗基因型为杂合子的患者,他有一个死于该病的侄子。在因子V莱顿突变杂合子个体中,aPL的存在可能导致进一步的活化蛋白C抵抗,从而增加血栓形成倾向。